Physician profile
Troy Payner
NPI 1922082866
$803,143.04
in general payments reported to CMS, 2019-2025
9 companies · $72K in 2025
The $72K reported for 2025 was more than what 96% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208K · 2020: $89K · 2021: $104K · 2022: $163K · 2023: $92K · 2024: $75K · 2025: $72K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $239K · Food and Beverage: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $238,874.25 |
| Food and Beverage | $345.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $802,899.15 | 2019-2025 | Sonopet Iq, Neptune, Core |
| Kls-Martin L.P. | $49.96 | 2021-2024 | |
| Zimmer Biomet Holdings, INC. | $48.53 | 2023-2025 | Htr-Pekk, Ti Rapidflap Spindown |
| Depuy Synthes Sales INC. | $45.60 | 2019-2025 | Matrixneuro, Matrixmandible, Synthecel |
| Ucb, INC. | $29.29 | 2019-2020 | |
| Abbott Laboratories | $24.30 | 2019 | |
| Aesculap, INC. | $17.85 | 2025 | M.Blue |
| Springworks Therapeutics, INC. | $14.64 | 2025 | Gomekli |
| Arbor Pharmaceuticals, INC. | $13.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Payner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.